Ten years with biologics: To whom do data on effectiveness and safety apply?

Rheumatology

Volumn 50, Issue 1, 2011, Pages 204-213

  Simard, Julia F ^a   Arkema, Elizabeth V ^a   Sundström, Anders ^a   Geborek, Pierre ^b   Saxne, Tore ^b   Baecklund, Eva ^c   Coster, Lars ^d   Dackhammar, Christina ^e   Jacobsson, Lennart ^b   Feltelius, Nils ^f,g   Lindblad, Staffan ^g   Rantapää Dahlqvist, Solbritt ^h   Klareskog, Lars ^g   van Vollenhoven, Ronald F ^a   Neovius, Martin ^a   Askling, Johan ^a,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f MEDICAL PRODUCTS AGENCY   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti tumour necrosis factor; Biologics; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritides

Indexed keywords

CYCLOSPORIN DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE REGISTRY; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SWEDEN; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 79951716374     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq326     Document Type: Article

References (14)

1. Neovius M, Simard J, Askling J, ARTIS Study Group. Nationwide prevalence of rheumatoid arthritis in Sweden. Ann Rheum Dis 2010;69(Suppl. 3):646.
2. Neovius M, Simard JF, SundströmAet al. Coverage and generalizability of the Swedish biologics register (ARTIS). Ann Rheum Dis 2010;69(Suppl. 3):646.
3. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. 3rd edition. Pacific Grove: Duxbury Press at Brooks/Cole Publishing Company, 1988.
4. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 2008;67:37-42.
5. Hetland ML, Lindegaard HM, Hansen A et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
6. Hjardem E, Hetland ML, Ostergaard M, Krogh NS, Kvien TK. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005;64:1220-3.
7. Kristensen L, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Characteristics of patients starting anti-TNF therapy for ankylosing spondylitis during a 9-year period in Southern Sweden. Ann Rheum Dis 2009; 68(Suppl. 3):630.
8. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:563-70.
9. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:iii-iv, xi-xiii, 1-229.
10. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
11. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
12. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76.
13. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
14. Askling J, Fored CM, Geborek P et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.